DAY 1
07.35 – 08.20 REGISTRATION
08.20 – 08.30 WELCOME & CHAIRPERSON’S OPENING REMARKS FOR DAY ONE
08.30 – 09.00
Platform fit for the non-platform molecules: simultaneous innovation of platform and process
• Merck has a drug substance manufacturing platform for biologics with state-of-the-art facilities that prioritize green and sustainable practices.
• Technological advances are integrated to manage the complexity of next-generation biologics.
• Platform fit for the non-platform molecules are discussed in case studies.
09.00 – 09.30
Implementing Filtration Technologies for Both Upstream and Downstream Unit Operations in Continuous Biomanufacturing
• Filtration plays critical roles in upstream and downstream continuous processing and presents unique challenges compared to traditional batch
manufacturing.
• Perfusion cell culture requires highly optimized filtration operations to ensure a high degree of product recovery while maintaining high through- put and cell viability.
• Continuous virus filtration (VF) is performed at a much lower flux and much higher throughput than most batch operations, presenting challenges
for both filter fouling and viral clearance.
Downstream Development
• Filtration plays critical roles in upstream and downstream continuous processing and presents unique challenges compared to traditional batch
manufacturing.
• Perfusion cell culture requires highly optimized filtration operations to ensure a high degree of product recovery while maintaining high through- put and cell viability.
Adipiscing Elit